当前位置: 首页 >> 检索结果
321. Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
作者: .;Christina Magnussen.;Jesus Alegre-Diaz.;Lubna A Al-Nasser.;Philippe Amouyel.;Larissa Aviles-Santa.;Stephan J L Bakker.;Christie M Ballantyne.;Antonio Bernabé-Ortiz.;Martin Bobak.;Paolo Boffetta.;Hermann Brenner.;Mattias Brunström.;Gunay Can.;Rodrigo M Carrillo-Larco.;William Checkley.;Jean Dallongeville.;Dirk De Bacquer.;Giovanni de Gaetano.;James A de Lemos.;Eleonora di Carluccio.;Annette Dobson.;Chiara Donfrancesco.;Marcus Dörr.;Eleonora d'Orsi.;Wojciech Drygas.;Robin P F Dullaart.;Gunnar Engström.;Marco M Ferrario.;Jean Ferrières.;Gemma A Figtree.;Bamba Gaye.;Majid Ghayour-Mobarhan.;Uri Goldbourt.;Clicerio Gonzalez.;Alina Gossling.;Guido Grassi.;Prakash C Gupta.;Jiang He.;Allison M Hodge.;Atsushi Hozawa.;Kristian Hveem.;Licia Iacoviello.;M Kamran Ikram.;Manami Inoue.;Vilma Irazola.;Modou Jobe.;Pekka Jousilahti.;Pontiano Kaleebu.;Maryam Kavousi.;Frank Kee.;Davood Khalili.;Jens Klotsche.;Wolfgang Koenig.;Anna Kontsevaya.;Sudhirsen Kowlessur.;Pablo Kuri-Morales.;Kari Kuulasmaa.;Sun-Seog Kweon.;Karl J Lackner.;Ulf Landmesser.;David M Leistner.;Carlos E Leiva Sisnieguez.;Darryl Leong.;Lars Lind.;Allan Linneberg.;Thiess Lorenz.;Magnus N Lyngbakken.;Reza Malekzadeh.;Sofia Malyutina.;Ellisiv B Mathiesen.;Patrick McElduff.;Olle Melander.;Andres Metspalu.;J Jaime Miranda.;Marie Moitry.;Joseph Mugisha.;Julia Munzinger.;Mahdi Nalini.;Vijay Nambi.;Peter M Nilsson.;Toshiharu Ninomiya.;Torbjørn Omland.;Sok King Ong.;Karen Oppermann.;Andrzej Pajak.;Luigi Palmieri.;Demosthenes Panagiotakos.;Sue K Park.;Mangesh S Pednekar.;Arokiasamy Perianayagam.;Annette Peters.;Hossein Poustchi.;Dorairaj Prabhakaran.;Andrew M Prentice.;Eva Prescott.;Arshed Quyyumi.;Ulf Risérus.;Satoko Sakata.;Martin Salazar.;Veikko Salomaa.;Susana Sans.;E Lilian P Sattler.;Ben Schöttker.;Aletta E Schutte.;Sadaf G Sepanlou.;Sanjib K Sharma.;Jonathan Shaw.;Leon A Simons.;Stefan Söderberg.;Abdonas Tamosiunas.;Roberto Tapia-Conyer.;Barbara Thorand.;Hugh Tunstall-Pedoe.;Jaakko Tuomilehto.;Raphael Twerenbold.;Diego Vanuzzo.;Giovanni Veronesi.;S Goya Wannamethee.;Masafumi Watanabe.;Jessica Weimann.;Philipp S Wild.;Yao Yao.;Yi Zeng.;Andreas Ziegler.;Francisco M Ojeda.;Stefan Blankenberg.
来源: N Engl J Med. 2025年
Five risk factors account for approximately 50% of the global burden of cardiovascular disease. How the presence or absence of classic risk factors affects lifetime estimates of cardiovascular disease and death from any cause remains unclear.
324. Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a).
作者: Steven E Nissen.;Wei Ni.;Xi Shen.;Qiuqing Wang.;Ann Marie Navar.;Stephen J Nicholls.;Kathy Wolski.;Laura Michael.;Axel Haupt.;John H Krege.; .
来源: N Engl J Med. 2025年392卷17期1673-1683页
Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepatic synthesis of lipoprotein(a), are unknown.
325. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
作者: Darren K McGuire.;Nikolaus Marx.;Sharon L Mulvagh.;John E Deanfield.;Silvio E Inzucchi.;Rodica Pop-Busui.;Johannes F E Mann.;Scott S Emerson.;Neil R Poulter.;Mads D M Engelmann.;Maria Sejersten Ripa.;G Kees Hovingh.;Kirstine Brown-Frandsen.;Stephen C Bain.;Matthew A Cavender.;Mette Gislum.;Jens-Peter David.;John B Buse.; .
来源: N Engl J Med. 2025年392卷20期2001-2012页
The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the cardiovascular efficacy of oral semaglutide in persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both is needed.
326. Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation.
作者: Sergio Raposeiras-Roubin.;Ignacio J Amat-Santos.;Xavier Rossello.;Rocío González Ferreiro.;Inmaculada González Bermúdez.;Diego Lopez Otero.;Luis Nombela-Franco.;Livia Gheorghe.;Jose L Diez.;Carlos Baladrón Zorita.;José A Baz.;Antonio J Muñoz García.;Victoria Vilalta.;Soledad Ojeda-Pineda.;José M de la Torre Hernández.;Juan G Cordoba Soriano.;Ander Regueiro.;Pascual Bordes Siscar.;Jorge Salgado Fernández.;Bruno Garcia Del Blanco.;Roberto Martín-Reyes.;Rafael Romaguera.;César Moris.;Sergio García Blas.;Juan A Franco-Peláez.;Ignacio Cruz-González.;Dabit Arzamendi.;Nieves Romero Rodríguez.;Felipe Díez-Del Hoyo.;Santiago Camacho Freire.;Francisco Bosa Ojeda.;Juan C Astorga Burgo.;Eduardo Molina Navarro.;Juan Caballero Borrego.;Valeriano Ruiz Quevedo.;Ángel Sánchez-Recalde.;Vicente Peral Disdier.;Eduardo Alegría-Barrero.;Javier Torres-Llergo.;Gisela Feltes.;José A Fernández Díaz.;Carlos Cuellas.;Gustavo Jiménez Britez.;Juan Sánchez-Rubio Lezcano.;Cristina Barreiro-Pardal.;Iván Núñez-Gil.;Emad Abu-Assi.;Andrés Iñiguez-Romo.;Valentín Fuster.;Borja Ibáñez.; .
来源: N Engl J Med. 2025年392卷14期1396-1405页
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However, most patients with valvular heart disease, including those undergoing transcatheter aortic-valve implantation (TAVI), have been excluded from randomized trials.
329. Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.
作者: Isabelle Mahé.;Marc Carrier.;Didier Mayeur.;Jean Chidiac.;Eric Vicaut.;Nicolas Falvo.;Olivier Sanchez.;Claire Grange.;Manuel Monreal.;Juan J López-Núñez.;Remedios Otero-Candelera.;Grégoire Le Gal.;Erik Yeo.;Marc Righini.;Helia Robert-Ebadi.;Menno V Huisman.;Frederikus A Klok.;Peter Westerweel.;Giancarlo Agnelli.;Cecilia Becattini.;Aristotelis Bamias.;Kostas Syrigos.;Sebastian Szmit.;Adam Torbicki.;Peter Verhamme.;Anthony Maraveyas.;Alexander T Cohen.;Cihan Ay.;Céline Chapelle.;Guy Meyer.;Francis Couturaud.;Patrick Mismetti.;Philippe Girard.;Laurent Bertoletti.;Silvy Laporte.; .
来源: N Engl J Med. 2025年392卷14期1363-1373页
In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and decreasing bleeding is unclear.
|